Villegas SL, Hernández LAJ

Language: Spanish
References: 17
Page: 108-113
PDF size: 395.84 Kb.

ABSTRACT

Background: Differentiated thyroid cancer is the most common malignant neoplasm of the endocrine system.
Objective: To know evolution of patients with differentiated thyroid carcinoma who underwent total thyroidectomy and the utility of recombinant human thyroid stimulating-hormone (rhTSH) as therapeutic and diagnostic tool in the treatment of thyroid carcinoma.
Matherials and methods: A retrospective descriptive-analytical study was made with differentiated thyroid cancer patients who underwent thyroidectomy. Inclusion criteria for patients were: completely-thyroidectomized individuals with histopathological diagnosis of differentiated thyroid carcinoma. An exclusion criterion for patients was undifferentiated thyroid cancer diagnosis with partial or total thyroidectomy.
Results: The most frequent tumor types were: the papillary type, followed for follicular variants of papillary, follicular and anaplastic thyroid carcinoma. Metastases were observed mainly in thyroid bed, cervical nodes, mediastinum, muscles and adipose tissue in the neck; rhTSH-associated effects were mild and observed in fewer patients.
Conclusion: The major tumor types were papillary and its follicular variants. In high risk cases or in patients with undetected tumor foci which were not eligible for surgical procedures, rhTSh may be used as therapeutic adjuvant and for early diagnosis of metastases.

REFERENCES

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-511.

2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-2648.

3. Tirado L, Granados M. Epidemiología y etiología del cáncer de la cabeza y el cuello. Cancerología 2007;2:9-17.

4. Jemal A, Siegel R, Ward E, Hao Y, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.

5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164- 2167.

6. Perfil epidemiológico de los tumores malignos en México. Secretaría de Salud 2011. Disponible en www.dgepi.salud. gob.mx

7. Dirección General de Información en Salud (DGIS). Base de datos defunciones 1979-2008. Sistema Nacional de Información en Salud (SINAIS). Disponible en www.sinais. salud.gob.mx

8. Consejo Nacional de Población (CONAPO). Proyecciones de la población en México CONTEO2005 1990-2012. Disponible en www.conapo.gob.mx.

9. McCaffrey TV, Bergstrahl E, Hay I. Locally invasive papillary thyroid cancer. Head Neck Surg 1994;16:165-172.

10. Nishida T, Nakao K, Hashimoto T. Local control in differentiated thyroid carcinoma with extrathyroidal invasion. Am J Surg 2000;179:86-91.

11. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1094.

12. Barbaro D, Boni G, Meucci G, Simi U, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-4115.

13. Singer PA, Cooper DS, Daniels GH, Ladenson PW, et al. Treatment guidelines for patients with thyroid nodules and well differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996;156:2165-2172.

14. Rosário PW, Borges MA, Purish S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I Is associated with lowered radiotoxicity. J Nucl Med 2008;49:1776-1782.

15. Robbins RJ, Robbins AK. Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-1938.

16. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637-3642.

17. Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997;82:11-14.